Lonza’s GlycoConnect® Technology for Best-in-Class ADCs: Emerging Clinical Insights

• Exploring how Lonza’s GlycoConnect® and HydraSpace® technologies enable ADCs with best-in-class therapeutic potential
• Sharing clinical development insights on the rapidly expanding and advancing pipeline of Lonza’s GlycoConnect® technology-based partnered ADC assets
• Discussing technology expansion towards high-DAR and dual-payload ADCs

Speakers:

Anette Sommer

Head of R&D, Bioconjugates Research

Lonza